source
- Vivoryon reclaims Chinese rights to kidney disease drug amid cash crunchVivoryon Therapeutics, a Munich-based biotech, has taken back the rights to develop its kidney disease candidate in China after a licensing arrangement with Simcere Pharmaceuticals. The original 2…
- Trump administration ends contracts with two No Surprises Act arbitrators over performance failuresThe federal government announced that two organizations that handle disputes under the No Surprises Act will no longer be allowed to accept new cases, saying they failed to meet required performanc…